title: New-Generation Thromboelastography: Comprehensive Evaluation of Citrated and Heparinized Blood Sample Storage Effect on Clot-Forming Variables.
abstract: BACKGROUND
  - Thromboelastography (TEG) is a whole blood, real-time analyzer measuring the viscoelastic properties of the hemostasis process and allowing for individualized goal-directed therapy. However, routine use of TEG requires validation of sample storage effect on clot parameters.
  
  
  OBJECTIVE
  - To establish the minimum time required for equilibration time and the maximum time for sample storage for all commercially available TEG tests for the new-generation TEG 6s and to determine how those times compare with the older generation TEG 5000.
  
  
  METHODS
  - Citrated and heparinized whole blood samples obtained from 20 healthy donors were analyzed for clot parameters at multiple time points for both the TEG 6s and the TEG 5000. Samples were activated with the citrated multichannel cartridge or the platelet-mapping cartridge in the TEG 6s or with recalcified kaolin in the TEG 5000.
  
  
  RESULTS
  - All blood samples yielded TEG parameter results within reference ranges and had a tendency toward hypercoagulable profiles with increased storage time. Sample storage resulted in increased platelet inhibition with significant differences at 4 hours in the platelet-mapping cartridge (arachidonic acid percentage of inhibition, P = .002; adenosine diphosphate percentage of inhibition, P = .02).
  
  
  CONCLUSIONS
  - For nonemergent cases or in a central laboratory setting, all tests provided reliable results for up to 4 hours in the citrated multichannel cartridge and for 3 hours for platelet function information in the platelet-mapping cartridge. In emergent/urgent situations in which the sample needs to be run immediately, RapidTEG and functional fibrinogen tests may be preferred.
authors.forename: Joao D
authors.initials: JD
authors.lastname: Dias
authors.forename: Elaine I
authors.initials: EI
authors.lastname: Haney
authors.forename: Blesy A
authors.initials: BA
authors.lastname: Mathew
authors.forename: Carlos G
authors.initials: CG
authors.lastname: Lopez-Espina
authors.forename: Adrian W
authors.initials: AW
authors.lastname: Orr
authors.affiliation: From the Department of Clinical Marketing, Haemonetics SA, Signy, Switzerland (Dr Dias); the Department of Scientific Research & Development, Haemonetics Corporation, Rosemont, Illinois (Mss Haney and Mathew and Mr Lopez-Espina); and the Department of Medical & Clinical Affairs, Haemonetics Corporation, Braintree, Massachusetts (Mr Orr and Dr Popovsky). Mr Orr is now with Anika Therapeutics Inc, Bedford, Massachusetts. Dr Dias and Ms Haney contributed equally to the design of this manuscript.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Popovsky
mesh_terms: D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects / Q000502:physiology*; D001800:Blood Specimen Collection / Q000379:methods*; D002951:Citrates / Q000737:chemistry* / Q000494:pharmacology; D005260:Female; D006493:Heparin / Q000737:chemistry* / Q000494:pharmacology; D006801:Humans; D007616:Kaolin / Q000737:chemistry / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D012016:Reference Values; D015203:Reproducibility of Results; D013916:Thrombelastography / Q000379:methods*; D013997:Time Factors; D055815:Young Adult
chemical_list: D002951:Citrates; D007616:Kaolin; D006493:Heparin